Deutsche Bank Aktiengesellschaft Increases Teladoc Health (NYSE:TDOC) Price Target to $12.00

Teladoc Health (NYSE:TDOC) had its price objective boosted by research analysts at Deutsche Bank Aktiengesellschaft from $10.00 to $12.00 in a report released on Friday, Benzinga reports. The firm currently has a “hold” rating on the health services provider’s stock. Deutsche Bank Aktiengesellschaft’s price objective would suggest a potential upside of 30.29% from the company’s current price.

TDOC has been the subject of several other research reports. Truist Financial decreased their price target on shares of Teladoc Health from $15.00 to $10.00 and set a “hold” rating for the company in a research note on Friday, August 2nd. Piper Sandler dropped their price target on Teladoc Health from $25.00 to $10.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Canaccord Genuity Group cut their price target on Teladoc Health from $25.00 to $17.00 and set a “buy” rating for the company in a research note on Thursday, August 1st. Evercore ISI boosted their price objective on Teladoc Health from $8.00 to $9.00 and gave the company an “in-line” rating in a research note on Tuesday, October 8th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $10.00 target price on shares of Teladoc Health in a research report on Tuesday, August 20th. Fourteen equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $11.97.

Teladoc Health Stock Up 2.3 %

TDOC stock opened at $9.21 on Friday. The stock has a market cap of $1.58 billion, a P/E ratio of -1.60 and a beta of 0.90. The company has a current ratio of 1.66, a quick ratio of 1.62 and a debt-to-equity ratio of 0.66. The stock’s fifty day simple moving average is $8.48 and its two-hundred day simple moving average is $9.69. Teladoc Health has a 1-year low of $6.76 and a 1-year high of $22.54.

Teladoc Health (NYSE:TDOC) last issued its quarterly earnings results on Wednesday, October 30th. The health services provider reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.10. Teladoc Health had a negative net margin of 37.91% and a negative return on equity of 9.40%. The company had revenue of $640.51 million for the quarter, compared to the consensus estimate of $630.50 million. Analysts expect that Teladoc Health will post -1.18 EPS for the current year.

Insider Activity

In related news, CFO Mala Murthy sold 8,750 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $7.16, for a total value of $62,650.00. Following the transaction, the chief financial officer now directly owns 85,767 shares in the company, valued at approximately $614,091.72. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CFO Mala Murthy sold 8,750 shares of Teladoc Health stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.16, for a total transaction of $62,650.00. Following the completion of the sale, the chief financial officer now directly owns 85,767 shares of the company’s stock, valued at approximately $614,091.72. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Thomas Mckinley bought 7,000 shares of Teladoc Health stock in a transaction that occurred on Tuesday, August 6th. The stock was purchased at an average cost of $7.57 per share, for a total transaction of $52,990.00. Following the purchase, the director now owns 31,077 shares of the company’s stock, valued at $235,252.89. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders sold 36,588 shares of company stock worth $268,831. 0.95% of the stock is currently owned by insiders.

Institutional Trading of Teladoc Health

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Point72 Asset Management L.P. lifted its stake in Teladoc Health by 221.9% in the second quarter. Point72 Asset Management L.P. now owns 5,303,123 shares of the health services provider’s stock worth $51,865,000 after purchasing an additional 3,655,436 shares during the last quarter. Rubric Capital Management LP bought a new stake in shares of Teladoc Health in the 2nd quarter valued at about $45,267,000. Clearline Capital LP boosted its holdings in Teladoc Health by 395.6% during the 2nd quarter. Clearline Capital LP now owns 4,364,201 shares of the health services provider’s stock valued at $42,682,000 after acquiring an additional 3,483,665 shares during the period. Assenagon Asset Management S.A. bought a new position in Teladoc Health during the 3rd quarter worth approximately $15,801,000. Finally, Bank of New York Mellon Corp increased its stake in Teladoc Health by 1.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 916,129 shares of the health services provider’s stock worth $8,960,000 after purchasing an additional 14,910 shares during the period. Hedge funds and other institutional investors own 76.82% of the company’s stock.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.